Conditions: Type 2 Diabetes Mellitus
Keywords: diabetes exenatide exendin-4 Amylin Lilly
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 69
Healthy volunteers: no

Brief summary:
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.

Detailed description:

Arms:
arm 1: Exenatide and Metformin arm 2: Insulin Glargine and Metformin

Interventions: intervention 1: exenatide intervention 2: Insulin glargine intervention 3: Metformin
Intervention descriptions: intervention 1: subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets intervention 2: subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets intervention 3: Patients usual dosage

Protocol document: